Advanced search
Publication Cover
Bioengineered Volume 13, 2022 - Issue 3
Submit an article Journal homepage
1,897
Views
0
CrossRef citations to date
0
Altmetric
Research paper

Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications

Shujuan XuDepartment of Surgery, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, PR ChinaCorrespondence[email protected]
View further author information
,
Fang WangDepartment of Surgery, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, PR ChinaView further author information
,
Hui LiDepartment of Surgery, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, PR ChinaView further author information
,
Ya WangDepartment of Surgery, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, PR ChinaView further author information
&
Dongzhong FangDepartment of Surgery, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, PR ChinaView further author information
Pages 4621-4633 | Received 15 Sep 2021, Accepted 16 Oct 2021, Published online: 21 Feb 2022

References

  • Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioor Med Chem. 2018;26(10):2700–2707
  • Craik DJ, Fairlie DP, Liras S, et al. The future of peptide-based drugs. Chem Biol Drug Des. 2013;81(1):136–147.
  • Zaman R, Islam RA, Ibnat N, et al. Current strategies in extending half-lives of therapeutic proteins. J Control Release. 2019;301:176–189.
  • Diao L, Meibohm B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet. 2013;52(10):855–868.
  • Mcgregor DP. Discovering and improving novel peptide therapeutics. Curr Opin Pharm. 2008;8(5):0–619.
  • Yao JF, Yang H, Zhao YZ, et al. Metabolism of peptide drugs and strategies to improve their metabolic stability. Curr Drug Metab. 2018;19(11):892–901.
  • Böttger R, Hoffmann R, Knappe D. Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum. PLoS One. 2017;12(6):e0178943.
  • Gentilucci L, De Marco R, Cerisoli L. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr Pharm Des. 2010;16(28):3185–3203.
  • Veronese FM, Mero A, Pasut G. Protein PEGylation, Basic science and biological applications. 2009, 11–31.
  • Pollaro L, Heinis C. Strategies to prolong the plasma residence time of peptide drugs. Med Chem Commun. 2010;1(5):319–324.
  • Fazavana J, Brophy TM, Chion A, et al. Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation. J Thromb Haemost. 2020;18(6):1278–1290.
  • Tian R, Zhu S, Zeng Q, et al. An albumin sandwich enhances in vivo circulation and stability of metabolically labile peptides. Bioconj Chem. 2019;30(6):1711–1723.
  • Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. AcBB. 2013;1830(12):5526–5534.
  • Zhong X, Yang S, Liu T, et al. Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics. Eur J Med Chem. 2018;S0223523418302952:  841-850.
  • Kim TH, Jiang HH, Lee S, et al. Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics. Bioconj Chem. 2011;22(4):625–632.
  • Xu S, Weng X, Wang Y, et al. Screening and preliminary validation of T lymphocyte immunoregulation‑associated long non‑coding RNAs in diabetic foot ulcers. Mol Med Rep. 2019;19(3):2368–2376.
  • Liang YH, Chang CC, Chen CC, et al. Development of an Au/ZnO thin film surface plasmon resonance-based biosensor immunoassay for the detection of carbohydrate antigen 15-3 in human saliva. Clin Biochem. 2012;45(18):1689–1693.
  • Zorzi A, Middendorp SJ, Wilbs J, et al. Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. Nat Commun. 2017;8(1):16092.
  • Rabbani G, Ahn SN. Structure, enzymatic activities, glycation and therapeutic potential of human serum albumin: a natural cargo. Int J Biol Macromol. 2019;123:979–990.
  • Maciążek-Jurczyk M, Szkudlarek A, Chudzik M, et al. Alteration of human serum albumin binding properties induced by modifications: a review. Spectrochim Acta A Mol Biomol Spectrosc. 2018;188:675–683.
  • Wan A, Miao Y, Peng L, et al. Binding and biologic characterization of recombinant human serum albumin-eTGFBR2 fusion protein expressed in CHO cells. Bioengineered. 2017;8(5):600–612.
  • Ishima Y, Maruyama T. Human serum albumin as carrier in drug delivery systems. Yakugaku Zasshi Journal of the Pharmaceutical Society of Japan. 2016;136(1):39–47.
  • Han J, Huang X, Sun L, et al. Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity. Biochem Pharmacol. 2013;86(2):297–308
  • Han J, Sun L, Huang X, et al. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability. Br J Pharmacol. 2014;171(23):5252–5264.
  • Lau J, Bloch P, Schaffer L, et al. The discovery of the once weekly glucagon like peptide 1 (GLP-1) analog semaglutide. J Med Chem. 2015;58(18): 7370-7380.
  • Holst JJ, Madsbad S. Semaglutide seems to be more effective the other GLP-1Ras. Ann Transl Med. 2017;5(24):505.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.